Business
Medicenna Announces Late Breaking Oral Presentation at the 2017 Congress of Neurological Surgeons (CNS) Annual Meeting
Medicenna Announces Late Breaking Oral Presentation at the 2017 Congress of Neurological S...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Announces Late Breaking Oral Presentation at the 2017 Congress of Neurological Surgeons (CNS) Annual Meeting\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-BOTTOM:black 0pt; TEXT-ALIGN: LEFT; BORDER-LEFT:black 0pt; PADDING-LEFT:0.50em; PADDING-RIGHT:0.50em; VERTICAL-ALIGN: TOP; BORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt\n}\n.prngen3{\nBORDER-BOTTOM:black 0pt; BORDER-LEFT:black 0pt; PADDING-LEFT:0.50em; PADDING-RIGHT:0.50em; VERTICAL-ALIGN: BOTTOM; BORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt\n}\n.prnsbt0{\nBORDER-TOP:0pt\n}\n.prnsbr0{\nBORDER-RIGHT:0pt\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n.prnsbl0{\nBORDER-LEFT:0pt\n}\n.prnsbb0{\nBORDER-BOTTOM:0pt\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, Sept. 25, 2017\n\n\n\nTORONTO and HOUSTON, Sept. 25, 2017 /CNW/ - Medicenna Therapeutics Corp. (\"Medicenna\" or the \"Company\") (TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. John Sampson M.D., Ph.D. MBA, Chair of the Department of Neurosurgery at Duke University Medical Centre will present at a Late Breaking Session during the Congress of Neurological Surgeons (CNS) Annual Meeting to be held from October 7-11, 2017 in Boston, MA.\n\nThe oral presentation by Dr. Sampson will provide an interim safety and tolerability evaluation of high flow convection enhanced delivery (CED) of the targeted immunotherapy MDNA55 in an early cohort of patients from the ongoing Phase 2b clinical study for the treatment of recurrent glioblastoma, the most common and deadly form of brain cancer. \n\nThe details of the presentation are as follows:\n\n\n\n\nTitle:\n\n\nReal time, image guided high flow CED in recurrent glioblastoma (rGBM); initial experience from phase II study of a targeted immunotherapy, MDNA55 (cpIL-4PE)\n\n\n\nDate:         \n\n\nTuesday, October 10, 2017\n\n\n\nTime:          \n\n\n7:48 AM\n\n\n\nSession:\n\n\nLate Breaking Abstract Session\n\n\n\nSession ID:\n\n\n250 (sub session 250-90)\n\n\n\nLocation:\n\n\n258...